Celldex Therapeutics vs Humacyte
Humacyte reported revenue of $2 million in fiscal 2025, 1.3 times Celldex Therapeutics' $2 million in fiscal 2025. Celldex Therapeutics had an operating margin of -18599.8%, against -5306.0% at Humacyte. Free cash flow was −$214 million at Celldex Therapeutics and −$106 million at Humacyte.
Side by side
| Celldex Therapeutics | Humacyte | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $2M | $2M |
| Revenue growth | −78.0% | — |
| Revenue growth a year, last 5 years | −27.3% | — |
| Gross margin | 87.1% | −376.1% |
| Operating margin | −18,599.8% | −5,306.0% |
| Net margin | −16,748.0% | −2,003.6% |
| Free cash flow | −$214M | −$106M |
| Free cash flow margin | −13,829.1% | −5,197.6% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 3.1% | 33.5% |
| Last close | $27.96 | $0.54 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $121,231 | bought $89,990, sold $41,298 |
| Piotroski F-score | — | 3 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Celldex TherapeuticsHumacyte
Operating margin
Percent of revenue
Celldex TherapeuticsHumacyte
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Celldex TherapeuticsHumacyte
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Celldex Therapeutics and Humacyte pages.